Physician profile
Christopher M Oconnor
NPI 1659455541
$160,547.62
in general payments reported to CMS, 2019-2025
9 companies · $51.93 in 2025
The $51.93 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $26K · 2021: $7,475 · 2022: $4,078 · 2023: $11K · 2024: $19K · 2025: $51.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $12K · Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,225.00 |
| Travel and Lodging | $12,305.83 |
| Food and Beverage | $887.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120,258.47 | 2019-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $22,658.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16,470.00 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $605.00 | 2022 | |
| Impulse Dynamics (USA) INC. | $180.54 | 2023 | Optimizer |
| Abbott Laboratories | $150.00 | 2019 | |
| Cvrx, INC. | $120.00 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $54.09 | 2024 | Wainua |
| Amgen INC. | $51.28 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.